Table 4.
Proportion of patients receiving no active treatment in the year following diagnosis, over time
| Overall cohort | RadOnc | Urologist alone | ||||
|---|---|---|---|---|---|---|
| No treatment (n, %) | Cohort | No treatment (n, %) | Cohort | No treatment (n, %) | Cohort | |
| Low-risk prostate cancer (Gleason ≤6, Stage 1 and PSA <10 ng/mL) | ||||||
| 2010 | 813 (70.5) | 1154 | 153 (41.0) | 373 | 660 (84.5) | 781 |
| 2011 | 992 (75.4) | 1316 | 163 (43.7) | 373 | 829 (87.9) | 943 |
| 2012 | 690 (82.5) | 836 | 93 (48.4) | 192 | 597 (92.7) | 644 |
| 2013 | 246 (78.3) | 314 | 39 (42.9) | 91 | 207 (92.8) | 223 |
| Trenda | Increase (p < 0.001) | No trend (p = 0.25) | Increase (p < 0.001) | |||
| Intermediate or high-risk prostate cancer (Gleason ≥7 or Stage ≥2, or PSA ≥10 ng/mL) | ||||||
| 2010 | 988 (24.5) | 4034 | 219 (12.3) | 1777 | 769 (34.1) | 2257 |
| 2011 | 1070 (22.9) | 4674 | 251 (11.8) | 2133 | 819 (32.2) | 2541 |
| 2012 | 711 (22.3) | 3184 | 162 (10.8) | 1507 | 549 (32.7) | 1677 |
| 2013 | 209 (18.1) | 1154 | 48 (7.1) | 633 | 161 (30.9) | 521 |
| Trenda | Decrease (p < 0.001) | Decrease (p = 0.002) | No change (p = 0.17) | |||
a Trend assessed using Cochran-Armitage test for trend